We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
Read MoreHide Full Article
Key Takeaways
CRISPR Therapeutics and Sirius start a phase II study of SRSD107 in thromboembolic disorders.
SRSD107 targets Factor XI to prevent venous thromboembolism in knee arthroplasty patients.
The collaboration expands CRISPR Therapeutics' pipeline into RNA therapeutics beyond gene therapies.
CRISPR Therapeutics (CRSP - Free Report) , along with privately held biotech, Sirius Therapeutics, announced the dosing of the first patient in a phase II study evaluating SRSD107, a next-generation, long-acting siRNA therapy for treating thromboembolic disorders in Europe.
SRSD107 targets Factor XI to treat thromboembolism, which affects millions of people across the world.
The ongoing randomized, multicenter phase II study is assessing the safety and efficacy of SRSD107 for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA).
Year to date, shares of CRISPR Therapeutics have rallied 57.7% compared with the industry’s rise of 3.5%.
Image Source: Zacks Investment Research
CRSP's Recent Deal With Sirius Therapeutics
In May 2025, CRISPR Therapeutics entered into a collaboration deal with Sirius Therapeutics for developing and commercializing novel siRNA therapies.
Per the deal terms, the companies will jointly develop SRSD107 and share all costs and profits equally. Upon potential approval, CRISPR Therapeutics will be responsible for commercializing the drug in the United States and Sirius Therapeutics in Greater China.
CRSP will also have an option to exclusively license up to two siRNA programs. It will solely fund research activities and retain opt-in rights to lead clinical development and commercialization for each target. Sirius Therapeutics will be entitled to receive milestone payments and tiered royalties on net sales.
If successfully developed, SRSD107 has the potential to be a best-in-class therapy for patients who are at risk of life-threatening thromboembolic events due to underlying co-morbid diseases such as malignancy, cardiovascular disease and hyper-coagulability.
The collaboration with Sirius Therapeutics has helped CRISPR Therapeutics diversify its pipeline beyond gene therapies and into RNA therapeutics.
CRSP's Casgevy Sales Gain Momentum
CRISPR Therapeutics and partner Vertex Pharmaceuticals’ (VRTX - Free Report) one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
VRTX leads global development, manufacturing and commercialization of Casgevy and splits program costs and profits worldwide with CRSP in a 60:40 ratio.
Though Casgevy’s sales started slowly, they are gaining momentum over time. In its second-quarter 2025 earnings release, Vertex recorded $30.4 million in product revenues from Casgevy sales, compared with $14.2 million in the previous quarter.
CRISPR Therapeutics is also advancing multiple next-generation gene-edited cell therapy programs, including allogeneic chimeric antigen receptor T cell, or CAR T, candidates for the treatment of hematological and solid tumor cancers and other autoimmune diseases.
CRSP's Zacks Rank & Stocks to Consider
CRISPR Therapeutics currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Akero Therapeutics’ 2025 loss per share have narrowed from $3.93 to $3.74. Loss per share estimates for 2026 have narrowed from $4.27 to $4.12 during the same period. AKRO stock has surged 66.8% year to date.
Akero Therapeutics’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 49.24%.
In the past 60 days, estimates for Adaptive Biotechnologies’ 2025 loss per share have narrowed from 87 cents to 71 cents. Loss per share estimates for 2026 have narrowed from 65 cents to 60 cents during the same period. ADPT stock has soared 132.5% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, the average surprise being 23.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
Key Takeaways
CRISPR Therapeutics (CRSP - Free Report) , along with privately held biotech, Sirius Therapeutics, announced the dosing of the first patient in a phase II study evaluating SRSD107, a next-generation, long-acting siRNA therapy for treating thromboembolic disorders in Europe.
SRSD107 targets Factor XI to treat thromboembolism, which affects millions of people across the world.
The ongoing randomized, multicenter phase II study is assessing the safety and efficacy of SRSD107 for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA).
Year to date, shares of CRISPR Therapeutics have rallied 57.7% compared with the industry’s rise of 3.5%.
Image Source: Zacks Investment Research
CRSP's Recent Deal With Sirius Therapeutics
In May 2025, CRISPR Therapeutics entered into a collaboration deal with Sirius Therapeutics for developing and commercializing novel siRNA therapies.
Per the deal terms, the companies will jointly develop SRSD107 and share all costs and profits equally. Upon potential approval, CRISPR Therapeutics will be responsible for commercializing the drug in the United States and Sirius Therapeutics in Greater China.
CRSP will also have an option to exclusively license up to two siRNA programs. It will solely fund research activities and retain opt-in rights to lead clinical development and commercialization for each target. Sirius Therapeutics will be entitled to receive milestone payments and tiered royalties on net sales.
If successfully developed, SRSD107 has the potential to be a best-in-class therapy for patients who are at risk of life-threatening thromboembolic events due to underlying co-morbid diseases such as malignancy, cardiovascular disease and hyper-coagulability.
The collaboration with Sirius Therapeutics has helped CRISPR Therapeutics diversify its pipeline beyond gene therapies and into RNA therapeutics.
CRSP's Casgevy Sales Gain Momentum
CRISPR Therapeutics and partner Vertex Pharmaceuticals’ (VRTX - Free Report) one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
VRTX leads global development, manufacturing and commercialization of Casgevy and splits program costs and profits worldwide with CRSP in a 60:40 ratio.
Though Casgevy’s sales started slowly, they are gaining momentum over time. In its second-quarter 2025 earnings release, Vertex recorded $30.4 million in product revenues from Casgevy sales, compared with $14.2 million in the previous quarter.
CRISPR Therapeutics is also advancing multiple next-generation gene-edited cell therapy programs, including allogeneic chimeric antigen receptor T cell, or CAR T, candidates for the treatment of hematological and solid tumor cancers and other autoimmune diseases.
CRSP's Zacks Rank & Stocks to Consider
CRISPR Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Akero Therapeutics (AKRO - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Akero Therapeutics’ 2025 loss per share have narrowed from $3.93 to $3.74. Loss per share estimates for 2026 have narrowed from $4.27 to $4.12 during the same period. AKRO stock has surged 66.8% year to date.
Akero Therapeutics’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 49.24%.
In the past 60 days, estimates for Adaptive Biotechnologies’ 2025 loss per share have narrowed from 87 cents to 71 cents. Loss per share estimates for 2026 have narrowed from 65 cents to 60 cents during the same period. ADPT stock has soared 132.5% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, the average surprise being 23.99%.